Oh, the COVID virus is a big moneymaker for those in the vaccine industry. It is a gift to these big pharma vultures so they can rake in fistfuls of cash and NEVER have to face a consequence of that damage their vaccines can do. They can literally, just pump everyone up with whatever, and then if someone is sick or has damage from the vaccine well they can’t be sued.
Pretty nice setup, don’t you think?
These vaccine makers are just giddy with the potential of this virus and all the things they can come up with that they know people will take since they are scared out of their minds with the virus.
If you thought forced vaccines and the neverending boosters were bad, well brace yourselves cause it is about to get much worse.
Pfizer is working on a new “twice a day” pill that you will take in addition to the vaccine and the never-ending boosters.
Seriously, what could possibly go wrong? Should I even utter those words since we all know everything could go wrong.
If you think I’m taking the jab, you’re dead wrong….but if you think I’m taking a twice-a-day pill from Pfizer you’ve done lost your mind!
Let’s take a look!
Albert Bourla is the Chairman and CEO of Pfizer….swell guy, I’m sure!
Also, here’s what he Tweeted:
Success against #COVID19 will likely require both vaccines & treatments. We’re pleased to share we’ve started a Phase 2/3 study of our oral antiviral candidate—specifically designed to combat SARS-CoV-2—in non-hospitalized, low-risk adults: https://t.co/su5VtfbWPX
— Albert Bourla (@AlbertBourla) September 1, 2021
Here’s the Press Release that accompanied his Tweet with all the nasty details of how Pfizer wants you gulping down their pills twice a day…..(for the rest of your life?):
First Participant Dosed in Phase 2/3 Study of Oral Antiviral Candidate in Non-Hospitalized Adults with COVID-19 Who Are at Low Risk of Severe Illness
New York, N.Y., September 1, 2021 – Pfizer Inc. (NYSE:PFE) today shared that the first participant has been dosed in a pivotal Phase 2/3 clinical trial to evaluate the safety and efficacy of PF-07321332 – an investigational orally administered protease inhibitor antiviral therapy designed specifically to combat COVID-19 – in non-hospitalized, symptomatic adult participants who have a confirmed diagnosis of SARS- CoV-2 infection and are not at increased risk of progressing to severe illness, which may lead to hospitalization or death.
The randomized, double-blind trial will enroll approximately 1,140 participants, who will receive PF- 07321332/ritonavir or placebo orally every 12 hours for five days.
Protease inhibitors, like PF-07321332, are designed to block the activity of the main protease enzyme that the coronavirus needs to replicate. Co-administration with a low dose of ritonavir is expected to help slow the metabolism, or breakdown, of PF-07321332 in order for it to remain in the body for longer periods of time at higher concentrations, thereby working continuously to help combat the virus. Ritonavir has previously been used in combination with other antivirals to similarly inhibit metabolism.
This study is part of a global clinical development program, consisting of multiple ongoing and planned clinical trials to evaluate this early-intervention, outpatient therapeutic candidate for potential use in a broad population of patients. The first registrational trial in this program, a pivotal Phase 2/3 study of PF- 07321332/ritonavir in non-hospitalized, symptomatic adult participants who have been diagnosed with SARS-CoV-2 infection and are at increased risk of progressing to severe illness, began enrollment in July 2021.
If successful, PF-07321332/ritonavir has the potential to address a significant unmet medical need, providing patients with a novel oral therapy that could be prescribed at the first sign of infection, without requiring hospitalization.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
But hey, I’m sure they will be super cheap too!
The good people over at InfoWars had more to report:
Pharmaceutical megacorporation pfizer is now developing a COVID pill that is meant to be taken alongside the COVID vaccines that have already made the company a staggering amount of money. The new pill is expected to be released by the end of the year and will be required to be taken twice per day.
“Success against #COVID19 will likely require both vaccines & treatments,” Pfizer CEO Albert Bourla said on Wednesday. “We’re pleased to share we’ve started a Phase 2/3 study of our oral antiviral candidate-specifically designed to combat SARS-CoV-2-in non-hospitalized, low-risk adults.”
Pfizer also put out a press release the same week that proclaimed, “If successful, [the drug] has the potential to address a significant unmet medical need, providing patients with a novel oral therapy that could be prescribed at the first sign of infection, without requiring hospitalization.” The company described the drug as an “investigational orally administered protease inhibitor antiviral therapy designed specifically to combat COVID–19 – in non–hospitalized, symptomatic adult participants who have a confirmed diagnosis of SARS–CoV–2 infection and are not at increased risk of progressing to severe illness, which may lead to hospitalization or death.”
Media corporations have already expressed excitement about the new pill, and Pfizer is so confident that the pill will be swiftly approved and mandated by governments that it has already started a production line before the end of clinical trials.
Other companies are also hard at work on COVID pills to be taken indefinitely while governments and media corporations focus on COVID.
In Singapore, a 16-year-old boy was ruled to be eligible for a $225,000 settlement this week after suffering a myocarditis cardiac arrest event that doctors ruled was likely in response to receiving his first dose of the Pfizer BionTech vaccine, with the Ministry of Health stating, “The myocarditis was likely a serious adverse event arising from the COVID-19 vaccine he received, which might have been aggravated by his strenuous lifting of weights and his high consumption of caffeine through energy drinks and supplements.”
I was so glad to see people waking up though in reply tweets like this:
Yeah, this isn’t going to happen for my family and I am quite sure most of you are feeling the same way. They can take their boosters and twice-a-day pills and shove them where the sun doesn’t shine.
If you want them by all means I am not going to stop you but I will caution you to truly research and just do not trust someone cause they have a Dr. by their name.